Skip to main navigation Skip to search Skip to main content

Ghrelin and synthetic GH secretagogues.

  • E ARVAT
  • , F. BROGLIO
  • , Gianluca AIMARETTI
  • , A BENSO
  • , R GIORDANO
  • , R DEGHENGHI
  • , E. GHIGO

Research output: Contribution to journalArticle

Abstract

Ghrelin, a 28-amino-acid acylated peptide, produced mainly by the stomach, displays strong growth hormone-(GH)-releasing activity mediated by the hypothalamus-pituitary growth hormone potential secretagogue (GHS) receptor which had been shown to be specific for a family of synthetic, orally active GHS. GHS are reliable provocative tests for the diagnosis of GH deficiency but, as orally active growth-promoting agents, they are not comparable with human recombinant GH in terms of efficacy. The usefulness of GHS in anabolic, anti-ageing drug intervention in the somatopause is still unclear. GHS also act on central and peripheral receptors and show other actions, including an orexigenic effect, an influence on gastroentero-pancreatic functions, and cardiovascular and anti-proliferative effects. Ghrelin mediates the neuroendocrine and metabolic response to starvation. Taking into account its orexigenic effect, GHS analogues acting as agonists or antagonists on appetite could represent a new drug intervention for eating disorders.

Original languageEnglish
Pages (from-to)505-517
Number of pages13
JournalBAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL ENDOCRINOLOGY & METABOLISM
Volume16(3)
Publication statusPublished - 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Ghrelin and synthetic GH secretagogues.'. Together they form a unique fingerprint.

Cite this